SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats

Behavioural Brain Research

Volumn 217, Issue 2, 2011, Pages 408-415

  de Bruin, N M W J ^a   Lange, J H M ^a   Kruse, C G ^a   Herremans, A H ^a   Schoffelmeer, A N M ^b   van Drimmelen, M ^a   De Vries, T J ^b  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 choice serial reaction time task (5 CSRTT); Cannabinoid CB1 receptor (CB1R) antagonist; Cue induced relapse; Ethanol; Nicotine; Self administration; SLV330; Wistar rats

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; SLV 330; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; BEHAVIOR CONTROL; CONDITIONED REFLEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; IMPULSIVENESS; INHIBITION (PSYCHOLOGY); MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; RESPONSE TIME; SUBSTANCE ABUSE;

ANALYSIS OF VARIANCE; ANIMALS; CONDITIONING, OPERANT; CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; ETHANOL; EXTINCTION, PSYCHOLOGICAL; MALE; NICOTINE; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SULFONAMIDES; TIME FACTORS;

EID: 78650420548     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.013     Document Type: Article

References (58)

1. Le Foll B., Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. The Journal of Pharmacology and Experimental Therapeutics 2005, 312(3):875-883.
2. Solinas M., Yasar S., Goldberg S.R. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacological Research 2007, 56(5):393-405.
3. Beardsley P.M., Thomas B.F., McMahon L.R. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. International Review of Psychiatry 2009, 21(2):134-142.
4. Fattore L., Fadda P., Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacological Research 2007, 56(November (5)):418-427.
5. Fattore L., Spano M.S., Deiana S., Melis V., Cossu G., Fadda P., et al. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Research Reviews 2007, 53(January (1)):1-16.
6. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology 2002, 13:451-463.
7. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, 132:104-106.
8. Hansson A.C., Bermúdez-Silva F.J., Malinen H., Hyytiä P., Sanchez-Vera I., Rimondini R., et al. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 2007, 32:117-126.
9. Malinen H., Hyytiä P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcoholism: Clinical and Experimental Research 2008, 32(11):1976-1983.
10. Cohen C., Kodas E., Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacology Biochemistry and Behavior 2005, 81(June (2)):387-395.
11. De Vries T.J., Schoffelmeer A.N.M. Cannabinoid CB1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences 2006, 26(August (8)):420-426.
12. Forget B., Coen K.M., Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB1 receptor blockade. Psychopharmacology (Berl) 2009, 205(4):613-624.
13. Colombo G., Vacca G., Serra S., Carai M.A.M., Gessa G.L. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. European Journal of Pharmacology 2004, 498(September (1-3)):119-123.
14. Wang L., Liu J., Harvey-White J., Zimmer A., Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age dependent decline in mice. Proceedings of National Academy of Sciences USA 2003, 100(3):1393-1398.
15. Thanos P.K., Dimitrakakis E.S., Rice O., Gifford A., Volkow N.D. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behavioural Brain Research 2005, 164(2):206-213.
16. Colombo G., Serra S., Vacca G., Carai M.A.M., Gessa G.L. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacology Biochemistry and Behavior 2005, 81(June (2)):369-380.
17. Carai M.A.M., Lobina C., Gessa G.L., Colombo G. Cannabinoid receptor antagonists: a perspective. Drugs for relapse prevention of alcoholism 2005, 181-187. R. Spanagel, K. Mann (Eds.).
18. Donny E.C., Caggiula A.R., Mielke M.M., Jacobs K.S., Rose C., Sved A.F. Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency. Psychopharmacology (Berl) 1998, 136:83-90.
19. Goldberg S.R., Spealman R.D., Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 1981, 214:573-575.
20. Caggiula A.R., Donny E.C., White A.R., Chaudhri N., Booth S., Gharib M.A., et al. Environmental stimuli promote the acquisition of nicotine self-administration in rats. Psychopharmacology (Berl) 2002, 163:230-237.
21. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, 30:145-155.
22. Maccioni P., Colombo G., Carai M.A.M. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. CNS and Neurological Disorders - Drug Targets 2010, 9:55-59.
23. de Bruin N.M.W.J., Prickaerts J., Lange J.H.M., Akkerman S., Andriambeloson E., de Haan M., et al. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and social recognition tasks in rodents. Neurobiology of Learning and Memory 2010, 93(May (4)):522-531.
24. Lange J.H.M., Coolen H.K.A.C., van Stuivenberg H.H., Dijksman J.A.R., Herremans A.H.J., Ronken E., et al. Synthesis, biological properties and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry 2004, 47:627-643.
25. Lange J.H.M, van Stuivenberg H.H., Veerman W., Wals H.C., Stork B., Coolen H.K.A.C., et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorganic and Medicinal Chemistry Letters 2005, 15:4794-4798.
26. Pattij T., Vanderschuren L.J.M.J. The neuropharmacology of impulsive behaviour. Trends in Pharmacological Sciences 2008, 29(4):192-199.
27. Krishnan-Sarin S., Reynolds B., Duhig A.M., Smith A., Liss T., McFetridge A. Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug and Alcohol Dependence 2007, 88:79-82.
28. Diergaarde L., Pattij T., Poortvliet I., Hogenboom F., de Vries W., Schoffelmeer A.N. Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats. Biological Psychiatry 2008, 63:301-308.
29. Pattij T., Janssen M.C.W., Schepers I., Gonzalez-Cuevas G., De Vries T.J., Schoffelmeer A. Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. Psychopharmacology 2007, 193:85-96.
30. O'Brien C.P., Gardner E.L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacology and Therapeutics 2005, 108:18-58.
31. Wallgren H., Barry H. Actions of alcohol 1970, Elsevier, Amsterdam.
32. De Vries T.J., Schoffelmeer A.N.M., Binnekade R., Vanderschuren L.J.M.J. Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. Psychopharmacology 1999, 143:254-260.
33. Stolerman I.P., Mirza N.R., Hahn B., Shoaib M. Nicotine in an animal model of attention. European Journal of Pharmacology 2000, 393:147-154.
34. Cippitelli A., Bilbao A., Hansson A.C., del Arco I., Sommer W., Heilig M., et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. European Journal of Neuroscience 2005, 21:2243-2251.
35. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2004, 30:145-155.
36. De Vries T.J., de Vries W., Janssen M.C.W., Schoffelmeer A.N.M. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behavioural Brain Research 2005, 161(June (1)):164-168.
37. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008, 54(2):438-444.
38. Le Foll B., Forget B., Aubin H., Goldberg S.R. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addiction Biology 2008, 13:239-252.
39. Thomas B.F. Research overview: neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists. Drug Development Research 2009, 70:527-554.
40. Goodman A. Neurobiology of addiction: an integrative review. Biochemical Pharmacology 2008, 75(January (1)):266-322.
41. Setlow B., Mendez I.A., Mitchell M.R., Simon N.W. Effects of chronic administration of drugs of abuse on impulsive choice (delay discounting) in animal models. Behavioural Pharmacology 2009, 20:380-389.
42. Jentsch J.D. Impulsivity in animal models for drug abuse disorders. Drug Discovery Today: Disease Models 2008, 5(4):247-250.
43. Hagn M. Untersuchung von Topiramat, Rimonabant, Orlistat und neuer Forschungschemikalien in verschiedenen Fettsuchtmodellen an Ratten: Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München, 2007.
44. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nature Reviews Drug Discovery 2008, 7:961-962.
45. Bifulco M., Pisanti S. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nature Reviews Drug Discovery 2009, 8:594.
46. Lee H.-K., Choi E.B., Pak C.S. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current Topics in Medicinal Chemistry 2009, 9(6):482-503.
47. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukotrienes and Essential Fatty Acids 2002, 66:101-121.
48. Scherma M., Panlilio L.V., Fadda P., Fattore L., Gamaleddin I., Le Foll B., et al. Inhibition of anandamide hydrolysis by URB597 reverses abuse related behavioral and neurochemical effects of nicotine in rats. The Journal of Pharmacology and Experimental Therapeutics 2008, 327(2):482-490.
49. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. Journal of Physiology and Pharmacology 2008, 59:217-228.
50. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Medicine 2003, 9:76-81.
51. Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., Casellas P. Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology 2005, 517(3):174-181.
52. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agrò A.F. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cellular and Molecular Life Sciences 2007, 64(2):219-229.
53. Ross R.A. Mini Review: anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology 2003, 140:790-801.
54. Maccarrone M., Barboni B., Paradisi A., Bernabò N., Gasperi V., Pistilli M.G. Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. Journal of Cell Science 2005, 118:4393-4404.
55. Schuel H. Tuning the oviduct to the anandamide tone. Journal of Clinical Investigation 2006, 116:2087-2090.
56. Wang H., Xie H., Guo Y., Zhang H., Takahashi T., Kingsley P.J. Fatty acid amide hydrolase deficiency limits early pregnancy events. Journal of Clinical Investigation 2006, 116:2122-2131.
57. Jentsch J.D., Taylor J.R. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl.) 1999, 146:373-390.
58. Racz I., Bilkei-Gorzo A., Toth Z.E., Michel K., Palkovits M., Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. Journal of Neuroscience 2003, 23:2453-2458.